These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11303006)

  • 21. The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.
    Lamy A; Wang X; Gao P; Tong W; Gafni A; Dans A; Avezum A; Ferreira R; Young J; Yusuf S; Teo K;
    J Med Econ; 2011; 14(6):792-7. PubMed ID: 21981559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How cost-effective are new preventive strategies for cardiovascular disease?
    Probstfield JL
    Am J Cardiol; 2003 May; 91(10A):22G-27G. PubMed ID: 12781905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Health care too costly? Saving more than 10 million euros in 2 months!].
    Rappert B
    MMW Fortschr Med; 2003 Nov; 145(47):65. PubMed ID: 14725043
    [No Abstract]   [Full Text] [Related]  

  • 24. [Therapy of hypertension. Cost conscious prevention of complications].
    Kolloch RE
    MMW Fortschr Med; 2003 Nov; 145(47):64. PubMed ID: 14725042
    [No Abstract]   [Full Text] [Related]  

  • 25. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HOPE study impact on ACE inhibitors use.
    Hemels ME; Bennett HA; Bonari L; Han D; Traverso ML; Einarson TR
    Ann Pharmacother; 2003 May; 37(5):640-5. PubMed ID: 12708937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study.
    Hart WM; Rubio-Terres C; Pajuelo F; González Juanatey JR
    Eur J Heart Fail; 2002 Aug; 4(4):553-8. PubMed ID: 12167396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HOPE for patients with Type 2 diabetes: an application of the findings of the MICRO-HOPE substudy in a British hospital diabetes clinic.
    Jones SC; Bowes PD; Hall E; Connolly V; Kelly WF; Bilous RW
    Diabet Med; 2001 Aug; 18(8):667-70. PubMed ID: 11553206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
    UK Prospective Diabetes Study Group
    BMJ; 1998 Sep; 317(7160):720-6. PubMed ID: 9732339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study.
    Ngalesoni FN; Ruhago GM; Mori AT; Robberstad B; Norheim OF
    BMC Health Serv Res; 2016 May; 16():185. PubMed ID: 27184802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.
    Can J Cardiol; 1996 Feb; 12(2):127-37. PubMed ID: 8605634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
    Gerstein HC
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical decision making and the expected value of information.
    Willan AR
    Clin Trials; 2007; 4(3):279-85. PubMed ID: 17715257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. More than just hype.
    Yusuf S; Dagenais G
    CMAJ; 2003 Jun; 168(13):1646; author reply 1647-8. PubMed ID: 12821614
    [No Abstract]   [Full Text] [Related]  

  • 39. Investigation of the effect of a countywide protected learning time scheme on prescribing rates of ramipril: interrupted time series study.
    Siriwardena AN; Fairchild P; Gibson S; Sach T; Dewey M
    Fam Pract; 2007 Feb; 24(1):26-33. PubMed ID: 17052988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
    Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
    Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.